Company / Cash & Equivalents
HealthEquity Cash & Equivalents History
FY2017-FY2026 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$318.9M
FY2026
5-year range
$225.4M / $404.0M
FY2022-FY2026
Trend
+0.0%
vs FY2025
Sector context
#64 of 148
Health Care
What the data says
At $319M, HealthEquity's cash & equivalents ranks #64 of 148 in the Health Care sector. Cash & Equivalents has fluctuated over the past 10 years, ranging from $192M in FY2019 to $404M in FY2023.
Based on SEC 10-K filings.
$319M in FY2026 with a 5-year CAGR of -0.6%.
Improved from $296M to $319M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -7.6%
- 5-Year CAGR
- -0.6%
- 10-Year CAGR
- -
Sector benchmark
#64 of 148 in Health CareTop 43% of 148This company $318.9M Sector average $1.2B
▼
-72.9% below sector average
Key checks
Key Insights
- 5-year CAGR of -0.6%, indicating a declining trend.
- In FY2026, cash & equivalents increased 0.0% year-over-year.
- Ranks #64 out of 148 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2023.
Company context
Key Data Points
- Altman Z-Score 1.18 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2026 | $318.9M | +0.0% |
| FY2025 | $318.9M | +7.8% |
| FY2024 | $295.9M | -26.7% |
| FY2023 | $404.0M | +79.2% |
| FY2022 | $225.4M | -31.4% |
| FY2021 | $328.8M | +0.0% |
| FY2020 | $328.8M | +71.5% |
| FY2019 | $191.7M | -47.0% |
| FY2018 | $361.5M | +81.2% |
| FY2017 | $199.5M | +42.5% |
As of FY2026 · SEC 10-K · Updated Jun 30, 2026